Preclinical development of a novel androgen receptor antagonist to treat castration-resistant prostate cancer

前列腺癌（PCa）是加拿大男性中最常见的非皮肤癌，也是癌症相关死亡的主要原因之一。在几乎所有患者中，前列腺癌的增殖和生长都是由雄激素受体（AR）驱动的。鉴于这一呼声，

Prostate cancer (PCa) is the most commonly diagnosed non-skin cancer in Canadian men and one of the leading causes of cancer-related death. In almost all patients, the proliferation and growth of PCa is driven by the androgen receptor (AR). Given this cri